Lineage Cell Therapeutics vs LENZ Therapeutics
LCTX and LENZ side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LCTX and LENZ compare
Lineage Cell Therapeutics is the larger company, worth 1.8 times as much as LENZ Therapeutics ($231M against $130M).
LENZ Therapeutics grew revenue faster over the last twelve months (330% versus 0.18% for Lineage Cell Therapeutics).
Lineage Cell Therapeutics keeps more of each dollar of sales as profit, with a net margin of 16.2% compared with −587% at LENZ Therapeutics.
LENZ Therapeutics scores higher on the StockData Score (9 against 8 for Lineage Cell Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LCTX | LENZ |
|---|---|---|
| Size and price | ||
| Market cap | $231M | $130M |
| Share price | $0.915 | $4.13 |
| Change, 1 year | −52.6% | −83.8% |
| Change, 5 years | −60.1% | −94.7% |
| Beta (5Y) | 0.96 | 1.08 |
| Employees | 77 | 152 |
| StockData Score | ||
| Total score | 8 | 9 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 3 (better) | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 21.3× | 6.0× (better) |
| P/B | 3.4× | 0.6× (better) |
| FCF yield | −11.4% (better) | −88.2% |
| Fair value | $0.620 | $7.62 |
| Margin of safety | −47.6% | 45.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 0.18% | 330% (better) |
| Revenue growth, 5Y average | 51.5% | – |
| Profitability | ||
| Operating margin | −280% (better) | −632% |
| Net margin | 16.2% (better) | −587% |
| FCF margin | −244% (better) | −533% |
| Return on equity | 3.9% (better) | −59.2% |
| Return on invested capital | −1395% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 5.96 | 13.55 (better) |
| Altman Z-score | −2.87 | 2.01 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 46.1% | 110% |
| Held by insiders | 74.4% | 6.7% |
| Insider net buying, 12 months | $24.4K (better) | −$8.8M |
| Short interest, % of float | 37.7% | 24.1% |
Go deeper
- LCTX stock overview
- LCTX income statement
- LCTX valuation and score
- LENZ stock overview
- LENZ income statement
- LENZ valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.